在IgA肾病患者中实施肾脏健康倡议替代疗效终点（PROTECT试验）。 - Suppr

Suppr

超能文献

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

作者信息

Barratt Jonathan, Rovin Brad, Diva Ulysses, Mercer Alex, Komers Radko

机构信息

Department of Cardiovascular Sciences, University of Leicester and Leicester General Hospital, Leicester, UK.

Department of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

出版信息

Kidney Int Rep. 2019 Aug 19;4(11):1633-1637. doi: 10.1016/j.ekir.2019.08.007. eCollection 2019 Nov.

DOI:10.1016/j.ekir.2019.08.007

PMID:31891005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6933476/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7283/6933476/bd6eb353028f/gr1.jpg

相似文献

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

Kidney Int Rep. 2019 Aug 19;4(11):1633-1637. doi: 10.1016/j.ekir.2019.08.007. eCollection 2019 Nov.

Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).

Pediatr Nephrol. 2019 May;34(5):837-846. doi: 10.1007/s00467-018-4099-8. Epub 2018 Oct 3.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.

Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy.

J Clin Lab Anal. 2000;14(5):220-3. doi: 10.1002/1098-2825(2000)14:5<220::AID-JCLA4>3.0.CO;2-2.

Recurrent IgA nephropathy in renal transplant allografts.

Am J Kidney Dis. 2001 Sep;38(3):588-96. doi: 10.1053/ajkd.2001.26885.

Treatment of IgA nephropathy: Recent advances and prospects.

Nephrol Ther. 2018 Apr;14 Suppl 1:S13-S21. doi: 10.1016/j.nephro.2018.02.010.

Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy.

Pediatr Res. 1996 Oct;40(4):620-6. doi: 10.1203/00006450-199610000-00018.

The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

Clin Nephrol. 2003 Nov;60(5):318-26. doi: 10.5414/cnp60318.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

引用本文的文献

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

PLoS One. 2025 Jun 10;20(6):e0323530. doi: 10.1371/journal.pone.0323530. eCollection 2025.

Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician.

Kidney Med. 2024 Nov 13;7(1):100928. doi: 10.1016/j.xkme.2024.100928. eCollection 2025 Jan.

State-of-Art Therapeutics in IgA Nephropathy.

Indian J Nephrol. 2024 Sep-Oct;34(5):417-430. doi: 10.25259/ijn_319_23. Epub 2024 Jun 24.

Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.

Kidney Int Rep. 2023 Oct 29;9(1):64-72. doi: 10.1016/j.ekir.2023.10.022. eCollection 2024 Jan.

Non-immunosuppressive treatment for IgA nephropathy.

Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.

Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

Kidney Int Rep. 2023 Feb 9;8(5):968-979. doi: 10.1016/j.ekir.2023.01.041. eCollection 2023 May.

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.

Circulation. 2023 May 30;147(22):1670-1683. doi: 10.1161/CIRCULATIONAHA.122.063327. Epub 2023 Apr 11.

Sparsentan: First Approval.

Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.

Kidney Int Rep. 2022 Aug 2;7(10):2150-2159. doi: 10.1016/j.ekir.2022.07.004. eCollection 2022 Oct.

本文引用的文献

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging.

Am J Kidney Dis. 2018 Dec;72(6):771-773. doi: 10.1053/j.ajkd.2018.08.017.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

作者信息

Barratt Jonathan, Rovin Brad, Diva Ulysses, Mercer Alex, Komers Radko

机构信息

Department of Cardiovascular Sciences, University of Leicester and Leicester General Hospital, Leicester, UK.

Department of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

出版信息

Kidney Int Rep. 2019 Aug 19;4(11):1633-1637. doi: 10.1016/j.ekir.2019.08.007. eCollection 2019 Nov.

DOI:10.1016/j.ekir.2019.08.007

PMID:31891005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6933476/

Abstract

摘要

相似文献

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial).

Kidney Int Rep. 2019 Aug 19;4(11):1633-1637. doi: 10.1016/j.ekir.2019.08.007. eCollection 2019 Nov.

Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).

Pediatr Nephrol. 2019 May;34(5):837-846. doi: 10.1007/s00467-018-4099-8. Epub 2018 Oct 3.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.

Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy.

J Clin Lab Anal. 2000;14(5):220-3. doi: 10.1002/1098-2825(2000)14:5<220::AID-JCLA4>3.0.CO;2-2.

Recurrent IgA nephropathy in renal transplant allografts.

Am J Kidney Dis. 2001 Sep;38(3):588-96. doi: 10.1053/ajkd.2001.26885.

Treatment of IgA nephropathy: Recent advances and prospects.

Nephrol Ther. 2018 Apr;14 Suppl 1:S13-S21. doi: 10.1016/j.nephro.2018.02.010.

Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy.

Pediatr Res. 1996 Oct;40(4):620-6. doi: 10.1203/00006450-199610000-00018.

The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

Clin Nephrol. 2003 Nov;60(5):318-26. doi: 10.5414/cnp60318.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

引用本文的文献

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

PLoS One. 2025 Jun 10;20(6):e0323530. doi: 10.1371/journal.pone.0323530. eCollection 2025.

Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician.

Kidney Med. 2024 Nov 13;7(1):100928. doi: 10.1016/j.xkme.2024.100928. eCollection 2025 Jan.

State-of-Art Therapeutics in IgA Nephropathy.

Indian J Nephrol. 2024 Sep-Oct;34(5):417-430. doi: 10.25259/ijn_319_23. Epub 2024 Jun 24.

Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.

Kidney Int Rep. 2023 Oct 29;9(1):64-72. doi: 10.1016/j.ekir.2023.10.022. eCollection 2024 Jan.

Non-immunosuppressive treatment for IgA nephropathy.

Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice.

Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

Kidney Int Rep. 2023 Feb 9;8(5):968-979. doi: 10.1016/j.ekir.2023.01.041. eCollection 2023 May.

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.

Circulation. 2023 May 30;147(22):1670-1683. doi: 10.1161/CIRCULATIONAHA.122.063327. Epub 2023 Apr 11.

Sparsentan: First Approval.

Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.

Kidney Int Rep. 2022 Aug 2;7(10):2150-2159. doi: 10.1016/j.ekir.2022.07.004. eCollection 2022 Oct.

本文引用的文献

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

Evaluation of Surrogate End Points for Progression to ESKD: Necessary and Challenging.

Am J Kidney Dis. 2018 Dec;72(6):771-773. doi: 10.1053/j.ajkd.2018.08.017.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.